Can Calming Inflammation Lift Stubborn Depression? A Small Trial Says Maybe

For decades, the standard story about depression has revolved around brain chemistry, and specifically around serotonin. That story is useful, but it leaves a stubborn group of patients out in the cold. Roughly a third of people with depression do not get better even after trying several antidepressants. What if, for some of them, the problem is not really happening in the usual places we look?

A new trial published in JAMA Psychiatry leans into a different idea [1]. The body's immune system, when it stays switched on for too long, may be feeding the low mood, the exhaustion, and the mental fog that define a depressive episode. If that link is real, then quieting the immune response might do something antidepressants cannot.

A drug borrowed from rheumatology

The researchers reached for tocilizumab, a drug already used to treat rheumatoid arthritis. It works by blocking interleukin-6, an inflammatory signaling molecule that tends to run high in people whose immune systems are agitated. Interleukin-6 has shown up repeatedly in depression research, which made it a logical target to test directly.

The study was led by Éimear M. Foley at the University of Bristol, working with colleagues including Golam M. Khandaker and a team spanning Bristol and Cambridge [2]. It was designed as a proof-of-concept randomized, double-blind, placebo-controlled trial. That design matters: neither the participants nor the people assessing them knew who got the real drug, which is the cleanest way to keep hope and expectation from coloring the results.

Who took part? The trial enrolled 30 adults with moderate-to-severe depression that had resisted treatment. Crucially, every participant also had elevated C-reactive protein, a blood marker that signals lingering inflammation. This was not a random slice of depressed patients. It was a deliberately selected group whose biology fit the theory being tested. Fourteen people received a single infusion of tocilizumab, and sixteen received a placebo.

What the numbers showed

Over four weeks, the people on tocilizumab tended to improve in a steady, stepwise way rather than all at once. By the end of the trial, about 54 percent of the treated group had reached remission, compared with roughly 31 percent in the placebo group [1]. The researchers translated that gap into a familiar clinical shorthand: the number needed to treat was five. In plain terms, you would treat about five patients to see one extra person reach remission who would not have gotten there on placebo.

The improvements were not limited to a single mood score. Participants reported less fatigue, sharper concentration, better appetite, and a softening of the harsh self-judgment that often comes with depression. Those are the symptoms that tend to grind people down day to day, so seeing movement there is meaningful, at least on paper.

Is this the long-promised proof that inflammation drives depression? Not quite. And the team behind the work would be the first to say so.

The reasons to stay cautious

Thirty people is a very small trial. With numbers that low, a few individual responses can swing the percentages dramatically, and the difference between groups, while encouraging, sits within the range where chance can still play tricks. A 54 percent versus 31 percent remission split sounds clean, but it rests on a handful of patients on each side.

There are other limits worth naming honestly. The follow-up ran only four weeks, so we have no idea whether the benefit holds, fades, or grows over months. The participants were specifically chosen for high inflammation, which means the findings cannot be stretched to depression in general. Most depressed people do not have raised C-reactive protein, and there is no reason to think an anti-inflammatory drug would help them. Tocilizumab is also a serious medication with real side-effect risks, including a dampened immune response, which is not a trivial trade-off for a four-week mood study.

A proof-of-concept trial is meant to answer one narrow question: is this idea worth pursuing with bigger, more expensive studies? On that score, the answer looks like yes. It is not a green light for prescribing, and it should not be read as one.

Why it still matters

What makes this work interesting is less the drug itself than what it suggests about matching treatment to biology. For years, depression care has largely been trial and error, cycling through medications until something sticks. A blood test that flags inflammation, paired with a treatment aimed at that specific mechanism, hints at a more targeted approach for a subset of patients who currently have few good options. The same logic of biology-first targeting is emerging in other areas too — a separate proof-of-concept study recently tested whether ketamine can relieve chronic fatigue, with comparably mixed but intriguing early results.

That vision is still a long way off. Larger trials need to confirm the effect, sort out who actually benefits, and weigh the risks against gentler alternatives. But the study adds a solid data point to a question that has hovered around psychiatry for a while now. Could inflammation be one of the things keeping certain people stuck? For at least some patients, the immune system may deserve a closer look than the standard chemical-imbalance framing has given it. Inflammation is not the only dietary or metabolic suspect in mood research either — recent work has explored whether poorly absorbed fructose might be driving anxiety through a similar gut-to-brain inflammatory route. For more emerging research on mental health biology, the evidence base is shifting fast.

Sources

1. Foley, É. M., Turner, N., Margelyte, R., Jones, H. J., Kaser, M., Lewis, G., Jones, P. B., & Khandaker, G. M. (2026). Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2026.1053
2. University of Bristol. (2026, May 27). Pilot trial suggests anti-inflammatory drug could help difficult-to-treat depression. https://www.bristol.ac.uk/news/2026/may/pilot-trial-suggests-anti.html

This article summarizes published research for general informational purposes only. It is not medical advice and should not be used to guide treatment decisions. Speak with a qualified healthcare professional about any health concern.